Semaglutide, marketed as Ozempic, Wegovy, and Rybelsus, is a GLP-1 receptor agonist approved by the FDA for type 2 diabetes and chronic weight management
Kaiser Northwest, for example, requires: (1) documented diet and exercise program, (2) failure of at least 2 weight loss medications (phentermine, Qsymia, Contrave, etc.), AND (3) a minimum 6-month trial of semaglutide (Wegovy or Ozempic) that was ineffective or not tolerated
A medical provider should review your health first
The principal mechanism of protraction resulting in the long half-life of semaglutide is albumin binding, which results in decreased renal clearance and protection from metabolic degradation
To ensure accurate and secure delivery, we recommend contacting our patient service representative as soon as possible if you need to change your shipping address